Ann: Imugene and Kincell Bio Announce Strategic Partnership, page-76

Selling for up to $6M in upfront and milestone payments.

While many people would be interested in what these exact figures are, no doubt, some of this information would be commercial in confidence, as it would relate to the manufacture of the drugs required to continue testing, and that would currently be a trade secret, would it not.
Therefore, some commercially sensitive information may be a trade secret and therefore protected from disclosure under Listing Rule 3.1A.
This would relate to both entities, so it would be a matter of what disclosures are being made under the other entity.

If in the end, the upfront and milestone payments do not meet close to the $6M, then it is likely that the product has failed, and this will not be at front of mind. However, if the entire $6M milestone payments have been made, then this will still not be front of mind, as everyone will be looking at the share price at the time, as it would likely mean that the product has met all its objectives and we are on a winner.

The fact that no one here knows the exact answer, is not a reason to have a go at the people here. It doesn't make them ignorant.
The best thing to do would be approach the company directly, if you are a shareholder, and ask the question directly.
Then share that answer.

Isn't that what someone did on another thread yesterday, and come back with all the answers, and quelled any concerns.